TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
07/04/2026
Voltar para busca
Dado oficial do USPTO
XENIUM
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
31
Atualização mais recente
09/04/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
1, 9, 42
Data de depósito
31/01/2023
Data de registro
22/10/2024
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
22/10/2024
Última transação
09/04/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use
Primeiro uso
08/12/2022
Primeiro uso no comércio
08/12/2022
Código do desenho
4
Tipo de titular
03
Localização do titular
Pleasanton, CA, US
Examinador
LINDEMYER, ANKHI MUKHERJEA
Unidade examinadora
N50
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
10X Genomics, Inc.
Representantes
Carla B. Oakley MORGAN, LEWIS & BOCKIUS LLP
Classificação técnica
Classes Nice
Classe 1Classe 9Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
reagentsassaysenzymeslabeled and unlabeled nucleic acids; monoclonal antibodies for in vitro screening and labeling of nucleic acids and proteins within tissue samples; buffer solutions for scientific and medical research purposes; kits comprised of reagents and reagent-treated glass slides for biological analysis for medical research and scientific research purposes; kits comprised of reagents and single-use laboratory bottles and laboratory pipette tips for scientific and medical research purposes; chemicalbiochemical and biological preparations for scientific and medical research purposes; combinations of multiple biochemical reagents commonly known as probeseach targeted to one or more biological analytes for detection of those biological analytes for scientific and medical research purposes
Classe 9
Laboratory equipmentinstruments for detection of biological molecules in tissue samplesvisualization of cellsdata analysis for scientific and medical research purposesin situ analyzers; recorded and downloadable computer software for the operation and control of scientific and medical research instruments; recorded and downloadable computer software for processingqualifyingquantifyingimaginganalysis or storage of medical and scientific research data and results regarding the spatial location or quantities of biological molecules in tissue samples; kits comprised of glass slides and reagents for scientific and medical research purposes
Classe 42
scientific research and development; scientific and technological research and development in the fields of spatial analysisin-situ detectiongenomicsproteomicstranscriptomicscell differentiationcell segmentationgene expression; providing scientific information in the fields of spatial analysisin-situ detectiongenomicsproteomicstranscriptomicscell differentiationcell segmentationgene expression; preparation of biological samples and assays for scientific and medical research; biological analysis of biological samples and assays for scientific and medical research; design and development of instruments for scientific analysisin situ analyzers; technical support services for computer software installationmaintenance and troubleshooting; providing scientific advice and consultancy in the fields of spatial analysisin-situ detectiongenomicsproteomicstranscriptomicscell differentiationcell segmentationgene expression
Publicações
Histórico de despachos e eventos da marca no USPTO.
31 publicações encontradas
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
07/04/2026
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
07/04/2026
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
22/10/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
22/10/2024
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
19/09/2024
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
19/09/2024
SUPC
STATEMENT OF USE PROCESSING COMPLETE
23/08/2024
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
22/08/2024
IUAF
USE AMENDMENT FILED
26/06/2024
EISU
TEAS STATEMENT OF USE RECEIVED
26/06/2024
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
26/12/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
31/10/2023
PUBO
PUBLISHED FOR OPPOSITION
31/10/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
11/10/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
20/09/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
20/09/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
20/09/2023
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
20/09/2023
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
01/08/2023
GNFR
FINAL REFUSAL E-MAILED
01/08/2023
CNFR
FINAL REFUSAL WRITTEN
01/08/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
29/06/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
28/06/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
28/06/2023
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
02/04/2023
GNRT
NON-FINAL ACTION E-MAILED
02/04/2023
CNRT
NON-FINAL ACTION WRITTEN
02/04/2023
DOCK
ASSIGNED TO EXAMINER
29/03/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
18/02/2023
NWAP
NEW APPLICATION ENTERED
03/02/2023
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace XENIUM ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.